Another trial for SIGA Technologies’ mpox antiviral has failed, and all enrollment has been stopped, the NIH’s National Institute of Allergy and Infectious Diseases announced …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.